Trial Profile
A Phase I, Open-Label, Prospective Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial(MA09-hRPE) Cells in Patients With Stargardt's Macular Dystrophy(SMD)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Apr 2024
Price :
$35
*
At a glance
- Drugs MA09 retinal pigment epithelial cell replacement therapy-Astellas Pharma (Primary)
- Indications Stargardt disease
- Focus Adverse reactions
- Sponsors CHA Bio & Diostech
- 06 Feb 2024 Status changed from active, no longer recruiting to completed.
- 24 Jun 2015 According to Ocata Therapeutics media release, pooled data from this and other four trials (see profiles 700243697, 700243711, 700255314, 700243638) has been presented as a Late Breaking Abstract at the International Society for Stem Cell Research (ISSCR) 13th Annual Meeting.
- 28 Apr 2015 New trial record